Georgetown Lombardi Comprehensive Cancer Center | Strategic Alliance Partners

May 06, 2021

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.

April 01, 2021

The Marshalls go beyond the pages of their new memoir, Off Our Chests: A Candid Tour Through the World of Cancer, to discuss how Liza's diagnosis of triple-negative breast cancer changed their lives and the key messages they hope readers will take from their book.

March 19, 2021

Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.

March 16, 2021

Michael B. Atkins, MD, discusses the FDA approval of tivozanib in relapsed/refractory advanced renal cell carcinoma.

March 06, 2021

Off Our Chests: A Candid Tour Through the World of Cancer is a memoir that dives into Liza Marshall’s breast cancer journey.

March 01, 2021

Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.

February 26, 2021

Geoffrey T. Gibney, MD, discusses efforts made to determine the optimal duration of treatment with anti–PD-1 agents in patients with melanoma.

February 15, 2021

John Marshall, MD, and his wife, Liza, recount the challenging journey of Liza's triple-negative breast cancer (TNBC) diagnosis and how John's career as a gastrointestinal oncologist played into the caregiving process. The interview comes ahead of the release of their book, Off Our Chests, which goes further in depth with their experience.

January 25, 2021

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

December 27, 2020

Stephen Liu, MD, discusses some pivotal data that support the expanding reach of targeted therapy in non–small cell lung cancer.

December 14, 2020

Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which immunotherapy has complicated treatment decisions, and more!

November 27, 2020

Joshua Reuss, MD, discusses the lung cancer armamentarium, the role of immunotherapy combinations, and the significance of biomarkers.

November 12, 2020

David H. Vesole, MD, PhD, discusses the mechanism of action of belantamab mafodotin-blmf in multiple myeloma.

November 04, 2020

It was 5:00 PM on a Monday, and Andrew Pecora, MD, FACP, CPE, was just wrapping up his practice for the day when one of his nurses came to the door, asking if he could see one more patient.

November 03, 2020

Julie M. Collins, MD, MPH, highlights key updates with targeted agents such as CDK4/6 and PI3K inhibitors in the treatment of patients with hormone receptor–positive breast cancer.

November 02, 2020

Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.

October 30, 2020

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

October 27, 2020

Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.

October 26, 2020

Michael B. Atkins, MD, discusses the impact of the Georgetown Lombardi Cancer Center Consortium on the treatment of patients with sarcoma.

October 26, 2020

Michael B. Atkins, MD, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.